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Available online 16 October 2008Flow cytometry with ﬂuorochrome-conjugated peptide-major histocompatibility complex
(pMHC) tetramers has transformed the study of antigen-speciﬁc T-cells by enabling their
visualization, enumeration, phenotypic characterization and isolation from ex vivo samples.
Here, we demonstrate that the reversible protein kinase inhibitor (PKI) dasatinib improves the
staining intensity of human (CD8+ and CD4+) and murine T-cells without concomitant
increases in background staining. Dasatinib enhances the capture of cognate pMHC tetramers
from solution and produces higher intensity staining at lower pMHC concentrations.
Furthermore, dasatinib reduces pMHC tetramer-induced cell death and substantially lowers
the T-cell receptor (TCR)/pMHC interaction afﬁnity threshold required for cell staining.
Accordingly, dasatinib permits the identiﬁcation of T-cells with very low afﬁnity TCR/pMHC
interactions, such as those that typically predominate in tumour-speciﬁc responses and
autoimmune conditions that are not amenable to detection by current technology.
© 2008 Elsevier B.V. Open access under CC BY license.Keywords:
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T-cells detect antigens in the form of peptides bound to
major histocompatibility complex (MHC) molecules at the cell
surface. This primary recognition event enables the orchestra-
tion of adaptive immunity and targeted destruction ofbility complex; TCR, T
ral bloodmononuclear
rus; EBV, Epstein-Barr
eath Park, Cardiff, CF14
ldridge).
ipt.
Y license.transformed and pathogen-infected cells. T-cell speciﬁcity is
determined by the highly variable complementarity determin-
ing regions of the T cell receptor (TCR). The TCR/peptide-MHC
(pMHC) interaction is very weak and classically endures for no
longer than a few seconds at physiological temperatures.
However, multimerization of pMHC molecules results in
cooperative interactivity at the cell surface and ensures that
the binding avidity of pMHC tetramers far exceeds the sum of
the contributing monomeric afﬁnities (Wooldridge et al., in
press). This avidity effect extends the binding half-life of pMHC
tetramers (Laugel et al., 2005) and enables stable coherence to
the surface of T-cells bearing cognate TCRs (Altman et al., 1996;
Burrows et al., 2000). Consequently, pMHC tetramers have
transformed the study of antigen-speciﬁc T-cells by enabling
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and isolation from ex vivo samples (Altman et al., 1996;
Chattopadhyay et al., 2006). Indeed, pMHC tetramers have
been used in thousands of studies in the decade since their
initial inception and have spawned the formation of several
commercial companies.
We have recently used a monoclonal T-cell system to
examine T-cell activation and pMHC class I (pMHCI) tetramer
binding with a series of altered peptide ligands that vary in
their afﬁnity for the cognate TCR by over 100-fold (Laugel et al.,
2007). Importantly, cell surface topography, including TCR and
CD8 density, remain constant in this system. In this controlled
system, efﬁcient staining with tetrameric pMHCI required a
monomeric TCR/pMHCI afﬁnity of KD b35μM; below this
threshold, there was a sharp drop off in the intensity of
pMHCI tetramer staining (Laugel et al., 2007). A reasonable T-
cell agonist in this system bound with a KD ~250μMand aweak
agonist bound with a KD N500μM. However, TCR/pMHCI
afﬁnities of N200μM were not detectable by pMHCI tetramer.
Thus, usingnormal stainingprocedures, pMHC tetramers donot
necessarily detect all T-cells that can respond to a particular
agonist; similarly, not all agonists for a particular T-cell can be
identiﬁed physically with pMHC tetramers. These potential
limitations of pMHC tetramer staining, which likely extend
across a range of multimeric valencies, have important implica-
tions for data interpretation and present a particular problem
for the detection of tumour-speciﬁc or autoreactive T-cells that
tend to express low afﬁnity TCRs (Cole et al., 2007).
In this study, we demonstrate that pre-treatment with a
protein kinase inhibitor (PKI) enhances pMHC tetramer
stainingof antigen-speciﬁc CD8+ andCD4+ T-cells anddescribe
the mechanism through which these effects operate. Impor-
tantly, these beneﬁts apply only toT-cells that express speciﬁc
TCRs; PKI treatment does not result in the staining of T-cells
that bear non-cognate TCRs. In addition, we show that PKI
treatment lowers the TCR/pMHCI afﬁnity threshold required
for pMHCI tetramer binding by as much as 5 fold, thereby
allowing the binding of pMHCI tetramers to CD8+ T-cells that
express TCRs with very weak afﬁnities for pMHCI (N500μM).
This simple and universally applicable procedure thereby
enables the visualization of previously undetectable tumour-
speciﬁc and autoreactive CD8+ T-cells with pMHCI tetramers
through the preferential enhancement of low avidity interac-
tions with TCRs at the cell surface.
2. Materials and methods
2.1. Cells
The ILA1 CTL clone is speciﬁc for the HLA A⁎0201 (HLA A2
from hereon) restricted human telomerase reverse transcrip-
tase (hTERT) epitope ILAKFLHWL (hTERT540-548). Mel13 and
Mel5 CTL clones are speciﬁc for the HLA A2 restricted Melan-
A26-35 epitope ELAGIGILTV. ILA1, Mel5 and Mel13 CD8+
cytotoxic T lymphocyte (CTL) clones were generated and re-
stimulated as described previously (Whelan et al., 1999; Laugel
et al., 2005). CTL were maintained in RPMI 1640 (Gibco)
supplemented with 100 U/ml penicillin (Gibco), 100μg/ml
streptomycin (Gibco), 10% heat inactivated fetal calf serum
(FCS; Gibco), 2.5% Cellkines (Helvetica Healthcare, Geneva),
200 IU/ml IL-2 and25ng/ml IL-15 (Peprotech). CTL lines speciﬁcfor the inﬂuenza matrix protein M158-66 (GILGFVFTL) and
Melan-A26-35 (ELAGIGILTV) epitopes, both restricted byHLAA2,
were generated by pulsing 6x106 PBMC from an HLA A2
individual with cognate peptide at concentrations of 1μM and
100μM, respectively, for 1 hour at 37 °C; cellswere subsequently
washed and resuspended in RPMI 1640 supplemented with
100U/mlpenicillin (Gibco),100 μg/ml streptomycin (Gibco) and
10% heat inactivated FCS (Gibco) only. After 3 days, increasing
amounts of IL-2 were added to themedia reaching amaximum
concentration of 20 IU/ml by day 14; lines were then tested by
pMHCI tetramer staining. Patient samples were collected by
leukapheresis; mononuclear cells were isolated by standard
Ficoll-Hypaque density gradient centrifugation and stored by
cryopreservation. For autoimmune studies, bloodwas obtained
from two HLA A2 patients with type 1 diabetes; both were
adults, aged 27 and 31 years, andwere studiedwithin 3months
of diagnosis. Short-term lines from these diabetic patients
were established as described above using the PPI15-24
autoantigen preproinsulin peptide (ALWGPDPAAA) (Skowera
et al., 2008); this peptide binds HLA A2with high afﬁnity (Arif
et al., 2004). Naïve murine CTL were obtained by harvesting
splenocytes from transgenic F5 Rag+ mice. A signiﬁcant
percentage of CD8+ T-cells within the splenic populations of
these mice express the F5 TCR, which recognizes the H-2Db-
restricted inﬂuenza H17-derived nucleoprotein peptide epi-
tope (ASNENMDAM) (Mamalaki et al., 1993). The HLA
DR⁎0101-restricted CD4+ T-cell clone C6 recognizes the
inﬂuenza virus A HA307-319 epitope (PKYVKQNTLKLAT).
2.2. Protein kinase inhibitors
Dasatinib was synthesized as described previously (Lom-
bardo et al., 2004). Biological activity was tested in a cell death
titration assay on BA/F3 bcr-abl cells as described previously
(Magnusson et al., 2002). Dasatinibwas dissolved in DMSO to a
concentration of 1 mM and stored in aliquots at −20 °C. Once
thawed, these stocks of dasatinib were stored at 4 °C and used
within 7 days. The 1 mM DMSO stock was diluted 1/10,000 in
PBS on the day of experimentation to achieve a working
solution of 100 nM; subsequent 1/2 dilution yielded a ﬁnal
concentration of 50 nM in cellular assays unless stated
otherwise. The 100 nM working solution was always made up
on the day of experimentation as the shelf-life of this solution is
short (~days). Staurosporine (Biomol), Lck inhibitor II (Calbio-
chem), genestein (calbiochem), herbimycin A (Calbiochem),
PP2 (Calbiochem) and PP3 (Calbiochem) were dissolved and
stored at −20 °C in DMSO. PKIs were dissolved in PBS prior to
use and tested at concentrations of 1 nM, 3 nM, 5 nM, 10 nM,
20 nM, 50 nM, 100 nM, 250 nM, 500 nM and 1μM.
2.3. pMHCI tetramer manufacture
Soluble biotinylated pMHCI monomers were produced as
described previously (Wooldridge et al., 2005). Tetrameric
pMHCI reagents were constructed by the addition of either R-
Phycoerythrin (PE)-conjugated streptavidin (Molecular Probes,
Invitrogen) or Alexa 488-conjugated streptavidin (Molecular
Probes, Invitrogen) at a pMHCI:streptavidin molar ratio of 4:1.
Conjugated streptavidin was added to a solution of soluble
pMHCI in 5 equal aliquots at 20min intervals and subsequently
stored in the dark at 4 °C.
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105 Mel13, Mel5 or ILA1 CTL were pre-treated at 37 °C with
dasatinib at a range of concentrations (0–50 nM) for a series of
durations up to 1 h.Mel13/Mel5 or ILA1were then stainedwith
either PE-conjugated HLA A2/ELAGIGILTV or HLA A2/
ILAKFLHWL tetramer, respectively, at a ﬁnal concentration of
10μg/ml for 20 min at 37 °C. The HLA DR⁎0101-restricted clone
C6 was stained with HLA DR⁎0101/PKYVKQNTLKLAT PE
tetramer for 20 min at 37 °C. After initial experiments to
determine the optimal conditions of use, all subsequent
experiments were performed by incubating T-cells±50 nM
dasatinib for 30 min at 37 °C prior to tetramer staining. Unless
otherwise stated dasatinib remained present throughout the
stainingprocedure. Subsequent to tetramer staining, CTL clones
were stained with anti-human CD8-FITC (clone SK1; BD
Pharmingen) and 7-AAD (Viaprobe; BD Pharmingen) for
30 min on ice then washed twice with phosphate buffered
saline (PBS); the HLA DR⁎0101-restricted clone C6 was stained
with 7-AAD (Viaprobe; BD Pharmingen) only. For murine CTL,
5x105 splenocytes were pre-treated with 50 nM dasatinib for
30 min at 37 °C, stained with H2-Db/ASNENMDAM PE-
conjugated tetramer for 20 min at 37 °C and then anti-murine
CD8-Cy5.5 for 30min on ice,washed twice and re-suspended in
PBS. Data were acquired using a FACSCalibur ﬂow cytometer
(BD)andanalyzedusing FlowJo software (Treestar Inc., Ashland,
OR, USA).
2.5. pMHCI tetramer staining and ﬂow cytometry: human
peripheral blood mononuclear cells
Frozen peripheral blood mononuclear cells (PBMCs) were
thawed in a37 °Cwater bathuntil a small clumpof ice remained
and then transferred into RPMI medium containing 10% FCS,
100 U/ml penicillin,100 μg/ml streptomycin, 2mML-glutamine
(Gibco) and 100 U DNase/ml (Roche Diagnostics Corporation,
Indianapolis, IN, USA). PBMC were washed twice in this me-
dium and then left to rest for 2 h at 37 °C. After 2 washes with
PBS, 2×106 PBMC were stained with live/dead® ﬁxable violet
amine reactive dye (Invitrogen Corporation, Carlsbad, Califor-
nia,USA),washedand incubated for 30min at37 °C in PBSalone
or PBS containing 50 nMdasatinib. Subsequently, PBMC in 50μl
of PBS alone or PBS containing 50nMdasatinibwere stained for
20 min with pHLA A2 tetramers refolded around either CMV
pp65495-503 (NLVPMVATV), EBV BMLFI259-267 (GLCTLVAML) or
Melan-A/Mart-126-35 (ELAGIGILTV) peptides. After 2 washes in
PBS containing 1% FCS and 0.02% sodium azide (Sigma-Aldrich,
St. Louis, MO, USA), cells were stained with a selection of the
following cell surface monoclonal antibodies (mAbs): (i) anti-
CD3-APC-Cy7 and anti-CD8-APC (BD Biosciences, San Jose, CA,
USA); (ii) anti-CD4-PE-Cy5.5 (Caltag Laboratories, purchased
through Invitogen Corporation, Carlsbad, California, USA); and,
(iii) anti-CD8-quantum dot (QD)705, anti- CD14-Paciﬁc Blue
and anti-CD19-Paciﬁc Blue, conjugated in-house according
to standard protocols (http://drmr.com/abcon/index.html). The
latter two mAbs were used to exclude CD14+ monocytes and
CD19+ B cells, which can bind tetramer non-speciﬁcally, from
the analysis. Finally, cells were washed and resuspended in PBS
containing 1% paraformaledehyde (PFA). Stained PBMC were
acquired on a BD LSR II (Becton Dickinson ImmunocytometrySystems, San Jose, CA, USA) and analyzed using FlowJo software
(Tree Star, Inc., Ashland, OR, USA).
2.6. TCR downregulation and tetramer on-rate experiments
HLA A2-expressing C1R B cells (Hutchinson et al., 2003)
were either pulsedwith ELAGIGILTV peptide at a concentration
of 10–6 M for 60 min at 37 °C or incubated in medium alone.
After two washes with RPMI 1640 supplemented with 100 IU/
ml penicillin and 100μg/ml streptomycin, 60,000 HLA A2+ C1R
cells (pulsed or unpulsed) were incubated for 4 h at 37 °C with
30,000 Mel13 CTL that had been pre-treated with PBS±50 nM
dasatinib for 30min at 37 °C. Cells were then stainedwith anti-
TCR-FITC (clone BMA 031; Serotec) and anti-CD8-APC (clone
RPA-T8; BD Pharmingen) for 30 min on ice, washed twice and
resuspended in PBS. Data were acquired using a FACSCalibur
ﬂow cytometer and analysed using FlowJo software (Treestar
Inc., Ashland, OR, USA). Tetramer on-rate experiments were
performed as previously described (Laugel et al., 2007).
2.7. Fluorescence microscopy
105 ILA1 CTL were treated with PBS±50 nM dasatinib for
30 min at 37 °C, then stained with Alexa 488-conjugated
(Molecular Probes) HLA A2/ILAKFLHWL tetramer at a ﬁnal
concentration of 20μg/ml for 15 min at 37 °C. Following two
washes with PBS, each sample was ﬁxed in 2% paraformalde-
hyde. After ﬁxing, ILA1 CTL were re-suspended in 100μl of 2%
FCS/PBS and then spun on to a microscope slide at 550 rpm for
5min using a cytospin. Sampleswere subsequently analysed on
a Leica DM LB2 (Leica Microsystems) ﬂuorescence microscope.
2.8. IFNγ ELISpot assays
CD8+ T-cell responses to islet autoantigen were detected by
IFNγ ELISpot as described previously (Chang et al., 2003) with
the followingmodiﬁcations. PBMCswere pre-cultured at 37 °C/
5% CO2 in single wells of 48-well plates at a density of
1×106 cells in 0.5 ml TC medium (RPMI 1640 supplemented
with antibiotics (Invitrogen) and 10% human AB serum (PAA,
Somerset, UK)) containing the test peptide at a ﬁnal concentra-
tion of 10μM. Control wells contained TC medium with an
equivalent concentration of diluent (DMSO). After 24 h incuba-
tion, non-adherent cells were re-suspended using pre-warmed
TCmedium (2% AB serum), washed, brought to a concentration
of 106 cells/300μl, and then dispensed in 100μl aliquots into
wells of 96-well ELISpot plates (Nunc Maxisorp; Merck Ltd.,
Poole, UK) pre-blocked with 1% bovine serum albumin in PBS
and pre-coated with monoclonal anti-IFNγ (U-Cytech, Utrecht,
NL). Assays were then developed according to the manufac-
turer's instructions; plates were dried and spots were counted
using a BioReader 3000 (BioSys, Karben, Germany) and
reported as total responder cells per 106 PBMCs.
2.9. Intracellular cytokine staining assays
106 CTL were stimulated with speciﬁc peptide at a concen-
tration of 10μg/ml for 6 h; brefeldin A (10μg/ml; Sigma-Aldrich)
was added for the ﬁnal 5 h. Unrelated peptide (10μg/ml) was
used as a negative control. Brieﬂy, the cells were ﬁxed in
paraformaldehyde (2%; Sigma-Aldrich), permeabilized with
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gated anti-TNFα mAb (BD Pharmingen). The cells were
evaluated using a FACSCalibur ﬂowcytometer (BD Biosciences).
At least 10,000 events gated on forward and side scatter were
analyzed using FlowJo software (Tree Star, Inc., Ashland, OR,
USA). Corresponding isotype control antibodies were used to
establish the quadrants for analysis.2.10. Mathematical modelling of the dasatinib effect on pMHCI
tetramer staining
Amathematicalmodel that relates staining intensity to tetra-
merbindingkineticshasbeendescribedpreviously (Laugel et al.,
2007; van den Berg et al., 2007). Brieﬂy, in this model, the high
binding avidityof pMHCI tetramers is accounted for byassuming
Table 1
Afﬁnity measurements of the interaction between the ILA1 TCR and
hTERT540-548 pMHCI variants
LIGAND 8E 5Y 4L Index 8Y 3G8T 3G
KD ILA1 TCR Binding (μM) N500 242 117 36.6 22.6 4.04 3.7
Summary of the results obtained by nonlinear analysis of surface plasmon
resonance binding equilibrium experiments as detailed in (Laugel et al., 2007)
and (Melenhorst et al., 2008). KD values were determined by analyzing the data
in nonlinear curve ﬁttings to the equation AB=BxABmax/(KD+B) assuming 1:1
Langmuir binding.
15A. Lissina et al. / Journal of Immunological Methods 340 (2009) 11–24that tetramers can engage up to three TCRmolecules, forming a
cluster of one, two, or three TCRs in which association and
dissociation between the TCRs and the tetramer pMHCI sites
occurs at amuchhigher rate thandiffusive escapeof temporarily
unbound TCRs, tending to stabilize the cluster until the tetramer
happens to become disassociatedwith TCRmolecules at all four
sites. Moreover, in singlet and duplet clusters, a free TCR can
associate contacts with free pMHCI sites to form, respectively, a
duplet or triplet cluster. The dasatinib effect is incorporated into
this model by assuming that dasatinib alters the rate at which
singlet andduplet clusters recruit freeTCRs. Thus, the expression
for the relative staining intensity I becomes:
I ¼ Imin þ ΔI K1=KDð Þr0 þ δD K2=KDð Þ3r20 þ δ2T K3=KDð Þ6r30
 
:
where KD is the single-site dissociation constant; K1, K2 and K3
are kinetic parameters; Imin and ΔI relate the read-out to the
number of surface bound tetramers (Imin is a nuisance
parameter, representing the background level); δD is the duplet
recruitmentenhancement factor and δT is the triplet recruitment
enhancement factor. In the absence of dasatinib, we have
δD=δT=1, whereas these factors are greater than 1 if dasatinib
promotes TCR recruitment. The scaled free TCR density, r0, is
implicitly deﬁned by the scaled conservation law:
1 ¼ r0 þ K1=KDð Þr0 þ 2δD K2=KDð Þ3r20 þ 3δ2T K3=KDð Þ6r30
(from Laugel et al., 2007). Association kinetics has been found
empirically tobedescribedverywell by thebiphasic exponential
model:
I tð Þ ¼ Imin þ Imax; fast 1−exp λfasttð Þð Þ þ Imax; slow 1−exp λslowtð Þð Þ
where I(t) is the staining intensity at time t and Imax, fast,
Imax, slow, λfast, and λslow are positive parameters (van den Berg
et al., 2007). The goodness of ﬁt is fair but not perfect (Fig. 2B);
a better curve ﬁt might be achievedwith amore sophisticated
model. However, we have taken a minimalistic approach to
modelling the dasatinib effect because of the mechanistic
uncertainties surrounding its mode of action. The duplet
recruitment enhancement factor δD was estimated to equal
6.53±2.93, whereas the triplet recruitment enhancement
factor δT was estimated to equal 13.7±7.38 (by simultaneous
non-linear least- squares). The ﬁt of the model indicates that
the data are consistent with the hypothesis that dasatinibFig. 1. Dasatinib substantially improves pMHC tetramer staining intensity. A. 105 ILA
(Calbiochem), then incubated at 37 °C for 30 min. Cells were then stained with cog
20 min at 37 °C, washed twice in PBS and analyzed on a FACSCalibur (BD) ﬂow cytom
after treatment with 50 nM dasatinib (blue) or LcK inhibitor II (red) compared to stain
various concentrations of dasatinib for 30 min at 37 °C, then stained with either HLA
20 min at 37 °C before washing with PBS. C. 105 ILA1 CTL were resuspended in 40μl
37 °C. Cells were then stained with cognate HLA A2/ILAKFLHWL-PE tetramer at a ﬁna
to ﬂow cytometric analysis. D. As (A), but ILA1 CTL were incubated with 50 nM
experiment the drug was washed off prior to staining. E. As (A), but tetramer concen
Mel13 CTL were stained with various concentrations of HLA A2/ELAGIGILTV tetramer
an F5 TCR transgenic Rag+ mouse were resuspended in PBS±50 nM dasatinib and
ASNENMDAM-PE tetramer for 20 min at 37 °C followed by anti-CD8 Cy5.5 for 30 min
of the HLA DR⁎0101-restricted, inﬂuenza virus A HA307-319 PKYVKQNTLKLAT-speciﬁc
then stained with cognate PE-conjugated tetramer for 20 min at 37 °C. Samples we
used as a negative control in all cases.makes free TCRsmore readily available to pMHCI tetramers for
recruitment into duplet and triplet clusters.
3. Results
3.1. PKI treatment enhances pMHC tetramer staining of CD8+
and CD4+ T-cells
Incubation of ILA1, a CTL clone speciﬁc for the HLA A2-
restricted epitope hTERT540-548 (ILAKFHWL), with the PKIs
dasatinib or 3-(2-(1H-benzo[d]imidazol-1-yl)-6-(2-morpho-
linoethoxy)pyrimidin-4-ylamino)-4-methylphenol (Lck inhi-
bitor II; Calbiochem) resulted in a N10 fold increase in pMHCI
tetramer staining intensity (Fig. 1A). Pre-incubation with the
PKI PP2 (Calbiochem) resulted in a moderate increase in
tetramer staining; however, no signiﬁcant enhancement was
observed when CTL were pre-treated with herbimycin, PP3,
genestein (Calbiochem) or staurosporine (Biomol) (data not
shown). Importantly, PKI inhibitor treatment did not enhance
staining with non-cognate pMHCI tetramer (Fig. 1B). Identical
results were obtained for the HLA A2-restricted Melan A26-35
ELAGIGILTV-speciﬁc CTL clone Mel13 (data not shown).
Dasatinib is an ATP-competitive, dual Src/Bcr-Abl kinase
inhibitor that has recently entered the clinic for the treatment
of chronic myelogenous leukaemia (CML) (Shah et al., 2004). In
addition, recent data shows that dasatinib can inhibit wild type
and mutant forms of KIT, a class III receptor tyrosine kinase. As a
result, dasatinibmayalsohavea role toplay indiseases associated
with KIT activation loop mutations such as systemic mastiocy-
tosis, acute myelogenous leukaemia (AML), seminoma, gastro-
intestinal stromal tumours andanalmelanomas (Schittenhelmet
al., 2006; Antonescu et al., 2007). Dasatinib has been shown to be
a potent inhibitor of the Src protein kinase Lck (IC50=0.4 nM)
(Carter et al., 2005; Weichsel et al., 2008). Furthermore, while1 CTL were re-suspended in 40μl of PBS±50 nM dasatinib or Lck inhibitor II
nate HLA A2/ILAKFLHWL-PE tetramer at a ﬁnal concentration of 10µg/ml for
eter. A N10-fold increase in median ﬂuorescence intensity (MFI) was observed
ing without PKI pre-treatment (green line). B. 105 ILA1 CTL were treated with
A2/ILAKFLHWL tetramer or the non-cognate HLA A2/ELAGIGILTV tetramer for
of PBS±the indicated concentration of dasatinib and incubated for 60 min at
l concentration of 10 μg/ml for 20 min at 37 °C and washed twice in PBS prior
dasatinib for various times prior to staining with pMHCI tetramer. For this
tration was varied to stain CTL pre-treated±50 nM dasatinib for 30 min. F. 105
following incubation±50 nM dasatinib for 30 min. G. 5x105 splenocytes from
incubated for 30 min at 37 °C. Cells were subsequently stained with H2-Db/
on ice prior to two washes in PBS and analysis by ﬂow cytometry. H. 105 cells
CD4+ clone C6 were incubated with PBS±50 nM dasatinib for 30 min at 37 °C,
re washed with PBS before ﬂow cytometric analysis. Irrelevant tetramer was
16 A. Lissina et al. / Journal of Immunological Methods 340 (2009) 11–24dasatinib reversibly inhibits antigen-speciﬁc T-cell effector
functions, it is not toxic to T-cells in the short term at
concentrations b100 nM (Weichsel et al., 2008). Indeed, T-cell
clones incubated in 50 nM dasatinib for 24 h were able to regain
responsiveness to antigen within 1 h of drug removal (data not
shown). Dasatinib can also be used in ﬂow cytometry-basedFig. 2. Dasatinib treatment preferentially increases the ability of pMHCI tetramers to stai
conjugated HLA A2 tetramer folded around the 8E, 5Y, 4L, index (ILAKFLHWL), 3G8Tor 3G
37 °C. For all samples, datawere acquiredwith a FACSCalibur ﬂowcytometer (BD) and ana
The MFI of tetramer staining for all of the variants in the presence and absence of das
interactionspreviouslymeasured foreachof thesevariants expressedas thedissociation coapplications without loss of cell viability (Weichsel et al., 2008).
These properties prompted us to select dasatinib for further
investigation in the current study.
The enhancement of pMHCI tetramer staining following
dasatinib treatmentwas highly dose dependent (Fig.1C). Maxi-
mal effect was achieved by exposing CTL to 50 nMdasatinib forn T-cells bearing low afﬁnity TCRs. A. 105 ILA1 CTL were stained with 10μg/ml PE-
peptides for 20min at 37 °C following incubation±50 nM dasatinib for 30min a
lyzed using FlowJo software. Irrelevant tetramerwas used as a negative control. B
atinib displayed in (A) are plotted against the monomeric afﬁnity of TCR/pMHC
nstant (KD) (Table1). Curveswereﬁttedasdescribed in theMaterials andmethodst
.
I
.
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staining intensity (Fig.1C). Unexpectedly, pre-incubation of CTL
with 50 nM dasatinib for as little as 30 s resulted in a 60%
increase in pMHCI tetramer staining (Fig. 1D). Furthermore,
incubation with 50 nM dasatinib for 30 min signiﬁcantly
enhanced the staining of both ILA1 and Mel13 CTL over a
wide range of pMHCI tetramer concentrations (Fig. 1E&F). Pre-
incubation with dasatinib also enhanced pMHCI tetramer
staining of naïve murine F5 TCR CTL directly ex vivo (Fig. 1G)
and pMHCII tetramer staining of a HLA DR⁎010-restricted CD4+
T-cell clone (Fig.1H). Thus, pre-incubationwith 50nMdasatinib
for 30 min provides a quick and easy way to enhance pMHC
tetramer staining efﬁciency in both human (CD4+ and CD8+
T-cells) and murine systems. These effects are highly speciﬁc;
increased pMHC tetramer binding only occurs in the presence
of a cognate TCR/pMHC interaction (Fig. 1B&H).
3.2. Dasatinib preferentially enhances pMHCI staining of T-cells
bearing low afﬁnity TCRs
In order to dissect further the effects of dasatinib, we exam-
ined pMHCI tetramer staining using several altered peptide
ligands for the ILA1 CTL clone that differ in their binding afﬁnity
for the ILA1 TCR by N100-fold (Table 1). Pre-incubation with
dasatinib enhanced staining efﬁciency with all variant pMHCI
tetramers (Fig. 2A). The percentage increase in tetramer staining
afforded by pre-incubation with dasatinib for 8E, 5Y, 4L, ILA
index, 3G8T and 3G pMHCI tetramers was 675%, 1825%, 324%,
111%, 75% and 26%, respectively. Thus, the beneﬁts of dasatinibFig. 3. Dasatinib reduces pMHCI tetramer-induced cell death. Increased tetramer stain
It is known that pMHCI tetramer-induced signaling can trigger cell death (Purbhoo e
death induced by tetramer staining was assessed using the amine-reactive viability d
ViViD. PBMCwere stainedwith ViViD to identify and allow exclusion of dead and dyin
after pMHCI tetramer and surface antibody staining. Datawere acquired on a BD LSR I
cells were excluded from the analysis and the frequency of GrViD-positive cells was a
ﬂow proﬁles are shown here for CD8+ T-cells speciﬁc for the HLA A2-restricted epito
frequencies of dead cells varied depending on the tetramer used, but the frequency of
lower in the presence of 50 nM dasatinib. These data, together with comparable resu
over the time course of a staining experiment could be substantially reduced by treapre-treatment in terms of enhanced tetramer staining intensity
are greater for peptide variants that exhibit weaker interactions
with the ILA1 TCR. The intensity of pMHCI tetramer staining in
the presence and absence of dasatinib treatment was plotted
against themonomeric TCR/pMHCI dissociation constants and a
curve ﬁtted according to the mathematical model outlined in
theMaterials andmethods (Fig. 2B). The data demonstrate that,
in the absence of dasatinib, there is a sharp reduction in
tetramer staining intensity for ligands with TCR/pMHCI KD N
35μM; this is consistent with previous observations (Laugel et
al., 2007). In the presence of dasatinib, however, the TCR/pMHCI
afﬁnity threshold for this sharp drop-off did not occur until the
KD exceeded 200μM. In fact, dasatinib treatment allows
detectable staining of the ILA1 clone even when the agonist
TCR/pMHCI KD exceeds 500μM. Dasatinib treatment therefore
enables the physical detection of CTL bearing TCRs with low
afﬁnity for the cognate pMHCI ligand that would otherwise be
undetectable using pMHCI tetramer staining alone.
3.3. Dasatinib reduces pMHCI tetramer-induced cell death
Previous studies have shown that soluble pMHCI tetramer-
induced signaling can trigger cell death (Purbhoo et al., 2001;
Xu et al., 2001; Guillaume et al., 2003; Cebecauer et al., 2005).
This can reduce the number of live cells that remain after
pMHCI tetramer staining under normal conditions. Dasatinib
blocks antigen-speciﬁc signaling and subsequent T-cell effector
functions (Weichsel et al., 2008). Consequently, we hypothe-
sized that dasatinib could prevent pMHCI tetramer-induced celling in the presence of dasatinib appears to be due partly to reduced cell death.
t al., 2001; Xu et al., 2001; Guillaume et al., 2003; Cebecauer et al., 2005). Cell
ye GrViD at the end of the staining procedure, which is spectrally distinct from
g cells prior to the addition of pMHCI tetramer; GrVID stainingwas performed
I ﬂowcytometer and analyzed using FlowJo software. ViViD+, CD14+ and CD19+
ssessed in the tetramer-positive CD3+CD8+ T-cell populations. Representative
pes CMV pp65495-503 (NLVPMVATV) and EBV BMLFI259-267 (GLCTLVAML). The
GrViD-positive dead cells within the tetramer-positive populationwas always
lts in other systems (data not shown), suggest that the cumulative cell death
tment with dasatinib.
Fig. 4.Dasatinib enhances the visualization of antigen-speciﬁc CD8+ T-cells inmixed cell populations. A. Staining ofHLAA2-restricted CTL lines expanded fromPBMC
by one round of stimulation with the inﬂuenza matrix M158-66 peptide (GILGFVFTL) or the Melan-A/Mart-126-35 peptide (ELAGIGILTV). Lines were stained with
cognate tetramer±pre-treatment with 50 nM dasatinib for 30 min at 37 °C. B. Flow cytometric proﬁles of live CD3+ lymphocytes stained with HLA A2 tetramers
folded around the EBV BMLF1259-267 (GLCTLVAML), CMV pp65495-503 (NLVPMVATV) or Melan-A/Mart-126-35 (ELAGIGILTV) peptide epitopes. 2x106 PBMC were
stainedwith the amine-reactive viability dye ViViD, then stainedwith tetramer (1μg inminimal staining volume)±pre-treatment with dasatinib for 30min at 37 °C.
Cells were then stained with cell surface markers as described in theMaterials andmethods; a dump channel was used to exclude dead cells, CD14+ and CD19+ cells
from the analysis. Boolean gating was carried out to exclude aggregates. Data were acquired with a BD LSR II ﬂow cytometer and analyzed using FlowJo software.
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died when PBMCs were stained directly ex vivo with pMHCI
tetramers representing epitopes derived from cytomegalovirus
(CMV) and Epstein-Barr virus (EBV) was reduced in the
presence of dasatinib (Fig. 3). Therefore, dasatinib exerts three
beneﬁcial effects: (i) it increases the intensity of pMHCI and
pMHCII tetramer staining; (ii) it preferentially enhances pMHCI
tetramer stainingof T-cells bearing lowafﬁnity TCRs; and, (iii) it
reduces pMHCI tetramer-induced cell death.3.4. Substantial improvements in the detection of antigen-speciﬁc
CD8+ T-cells directly ex vivo
The above ﬁndings suggest that dasatinib treatment might
enable the identiﬁcation of low avidity antigen-speciﬁc CD8+
T-cells directly ex vivo that cannot be ‘seen’ in the absence of
the drug. To test this idea, we ﬁrst examined the staining of
CTL lines in the presence or absence of 50 nM dasatinib.
Staining improvements were observed in three different CTL
Fig. 5.Dasatinib allows detection of autoreactive CTL. A. CTL clone IE6, speciﬁc for the HLA A2-restricted epitope PPI15-24, was activatedwith either CMV pp65495-503
or PPI15-24 peptide for 6 h at 37 °C and then assayed for TNFα production by intracellular cytokine staining as detailed in the Materials and methods. B. Staining of
CTL clone IE6 with either an irrelevant or HLA A2/PPI15-24 tetramer±pre-treatment with 50 nM dasatinib for 30 min at 37 °C. C. Representative stainings with HLA
A2/PPI tetramer±pre-treatment with 50 nM dasatinib for 30 min at 37 °C. Left panels: control subject PBMCs; middle panels: type I diabetic patient PBMCs; right
panels: a short-term line expanded by one round of peptide stimulation from a type 1 diabetic patient.
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Fig. 6. Dasatinib results in a time dependent increase in TCR and CD8 expression levels at the CTL cell surface. The ILA1 CTL clone was treated with PBS±50 nM
dasatinib at 37 °C and 105 CTL were removed from the medium at 0, 10, 30, 60, 180 and 250 min. CTL were subsequently stained with anti-CD8 FITC (clone SK1; BD,
Pharmingen; left panel) or anti-TCR FITC (clone BMA 031; Serotec; right panel) for 30 min on ice, washed twice and resuspended in PBS. Data were acquired on a
FACSCalibur ﬂow cytometer (BD) and analyzed using FlowJo software.
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GILTV) and three different CTL lines stimulated with the
inﬂuenza matrix M158-66 epitope (GILGFVFTL), all derived
from HLA A2+ individuals. Representative data are shown in
Fig. 4A. In all cases, dasatinib treatment substantially enhanced
the staining intensity of cognate CD8+ T-cells without con-
comitant increases in the tetramer-negative population. In
accordance with the results above, CD8+ T-cells that stainedFig. 7. Beneﬁcial effects of dasatinib are not CD8-mediated. A. Melc5 CTL were pre- tre
DT227/8KA cognate tetramer for 20 min at 37 °C. After washing twice, data were
software. B. Staining of HLA A2-restricted CTL lines expanded from PBMC by one rou
were stained with either wild type or CD8 null cognate tetramer±pre-treatment wpoorlywithpMHCI tetramerexhibited the greatest beneﬁt from
dasatinib treatment. The staining intensity of all cognate CD8+
T-cells increased by at least 2-fold after dasatinib treatment, but
T-cells that bound tetramer weakly exhibited increases of N20-
fold in their ﬂuorescence intensity. In many cases, larger
populations of cells that stained with the corresponding
pMHCI tetramer were detected after dasatinib treatment. This
increase in tetramer+ cells after dasatinib treatment likelyated with PBS±50 nM dasatinib for 30min at 37 °C, then stained with HLA A2
acquired on a FACSCalibur ﬂow cytometer (BD) and analyzed using FlowJo
nd of stimulation with the Melan-A/Mart-126-35 peptide (ELAGIGILTV). Lines
ith 50 nM dasatinib for 30 min at 37 °C.
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terms of TCR/pMHCI afﬁnity and the fact that dasatinib reduces
pMHCI tetramer-induced cell death (Fig. 3). Subsequently, we
examined whether dasatinib could enhance pMHCI tetramer
staining of cognate CD8+ T-cells in direct ex vivo PBMC samples
and enable the detection of antigen-speciﬁc CD8+ T-cells thatFig. 8. Dasatinib blocks antigen-induced TCR downregulation and tetramer internali
dasatinib and exposed to C1R-A2 B cells previously pulsed with 10-6M ELAGIGILTV p
anti-TCR-FITC (clone BMA 031; Serotec) and anti-CD8-APC (clone RPA-T8; BD Pharm
were acquired on a FACSCalibur ﬂow cytometer (BD) and analyzed using FlowJo softw
(iii & iv) for 30 min at 37 °C, then stained with 20μg/ml HLA A2/ILAKFLHWL-Alexa48
Materials and methods.are 'invisible' with routine staining procedures. Indeed, a
substantial increase in both pMHCI staining intensity and the
percentage of antigen-speciﬁc CD8+ T-cells was observed at
both 4 °C and 37 °C in PBMC samples stained with HLA A2
tetramers speciﬁc for antigens derived from CMV, EBV and
Melan A (Fig. 4B).zation from the cell surface. A. Mel13 CTL were pre-treated with PBS±50 nM
eptide or medium alone for 4 h at 37 °C. Cells were subsequently stained with
ingen) mAbs for 30 min on ice, washed twice and resuspended in PBS. Data
are. B.105 ILA1 CTL were pre-treated with PBS (i & ii) or PBS+50 nM dasatinib
8 tetramer for 15 min at 37 °C. Microscopy was performed as described in the
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dasatinib treatment
We next examined pMHCI tetramer staining of IE6, a pre-
proinsulin (PPI15-24)-speciﬁcHLAA2- restricted autoreactiveCTL
clone isolated fromapatientwith type1diabetes. This CTL clone
produces TNFα, IFNγ andMIP1β on stimulationwith target cells
pulsed with cognate PPI-derived peptide antigen (Fig. 5A), and
does not stainwith cognate pMHCI tetramer using conventional
staining procedures (Fig. 5B). An identical result was obtained
for 2D6, a different PPI-speciﬁc CTL clone isolated from a patient
with type I diabetes (data not shown). Dasatinib treatment
allowed both CTL clones to bind cognate tetramer without
affecting stainingwith non-cognate tetramer (Fig. 5B & data not
shown). In keeping with these ﬁndings, dasatinib treatment
allowed the identiﬁcation of aHLAA2/PPI15-24 tetramer-positive
population directly ex vivo from a type I diabetic patient,
consistentwith a corresponding IFNγ ELISpot response to PPI15-
24 peptide of 13 responder cells per 106 PBMCs (Fig. 5C&data not
shown). Dasatinib did not increase direct ex vivoHLAA2/PPI15-24
tetramer staining in healthy HLA A2-matched control subjects
(Fig. 5C). A seven-fold increase in the percentage of autoreactive
CTL was observed when short-term lines expanded from two
type I diabetic patientswere stained in the presence of dasatinib
(Fig. 5C & data not shown). Thus, dasatinib treatment allows the
detection of functional autoreactive CTL that are otherwise
undetectable with standard staining conditions.
3.6. How does dasatinib exert its beneﬁcial effects on pMHC
tetramer staining?
Previous studies have demonstrated that incubationwith Src
kinase inhibitors results in enhanced TCR and CD8 expression at
the cell surface (Luton et al., 1994; D'Oro et al., 1997). Consistent
with these observations, we have recently demonstrated that
increased levels of TCR and CD8 are seen at the cell surface
following incubation with dasatinib for 4 h (Weichsel et al.,
2008). Initially, therefore, we investigated this increase in TCR
and CD8 levels as a possible mechanism for the observed effectsFig. 9. Dasatinib enhances pMHCI tetrameron-rate. Rate ofHLAA2/hTERT540-548
(ILAKFLHWL) tetramer recruitment to the cell surface of clone ILA1 is sub-
stantially enhanced following treatment of CTL with 50 nMdasatinib for 30min
at 37 °C. Subsequent to treatment with dasatinib, on-rate experiments were
performed and analyzed as described previously (Laugel et al., 2007). Curves
represent the following rate estimates: fast rate 0.14/min, slow rate 0.04/min
(tetramer only); fast rate 0.42/min, slow rate 0.06/min (dasatinib+tetramer).on tetramerbinding. Thebeneﬁcial effects of dasatinibonpMHCI
tetramer staining were observed within seconds of dasatinib
treatment (Fig.1D),whereas signiﬁcant increases inTCRandCD8
levels were not observed until N30 min (Fig. 6). Therefore, this
time dependent accumulation of TCR and CD8 at the cell surface
cannot explain the effects of dasatinib on tetramer binding.
We next investigated whether the mechanism of PKI action
operates through TCR- or CD8-mediated effects. Dasatinib
treatment enhanced pMHCI tetramer staining of the HLA A2-
restricted ELAGIGILTV-speciﬁc Melc5 CTL clone and a CTL line
raised against the Melan-A/Mart-126-35 epitope (ELAGIGILTV)
with both wildtype and CD8-null (DT227/8KA) tetramers
(Fig. 7A&B), thereby demonstrating that PKIs can exert their
effects in the absence of a pMHCI/CD8 interaction. Thus,
consistent with effects on pMHCII tetramer binding (Fig. 1),
dasatinib does not enhance pMHCI tetramer binding via CD8-
mediated effects.
TCR expression levels are not static and TCRs are constantly
being down-regulated from the cell surface (Krangel, 1987). TCR
internalization is thought to be mediated by three different
mechanisms: (i) constitutive recycling of the TCR between
intracellular compartments and theplasmamembrane in resting
cells by an unknown mechanism (Dietrich et al., 2002); (ii)
protein kinase C activation (Minami et al., 1987; Dietrich et al.,
2002); and, (iii) lck-mediated tyrosine phosphorylation follow-
ing TCR ligation by speciﬁc pMHCI ligand. Dasatinib has been
shown to target lck and therefore has the potential to inhibit the
latter pathway of TCR down-regulation. Indeed, dasatinib
treatment was found to block antigen-induced TCR down-
regulation from the CTL surface (Fig. 8A). pMHC tetramers are
rapidly internalized under normal staining conditions (Whelan
et al.,1999) and thereforewe reasoned that dasatinibmight exert
its beneﬁcial effects by blocking this process. To this end,
ﬂuorescence microscopy was performed in the presence and
absence of dasatinib (Fig. 8B). HLA A2/ILAKFLHWL-Alexa488
tetramer capping and internalization was blocked in the
presence of dasatinib and remained on the cell surface where it
formed a ring that was visibly brighter than tetramer that had
been internalized (Fig. 8B). Thus, by preventing TCR down-
regulation, PK inhibition acts to drive the system towards a
higher number of surface TCRs and a higher number of potential
productiveengagementswithpMHCtetramer. Thishas theeffect
of increasing tetramer on-rate, at least in pMHCI systems (Fig. 9).
4. Discussion
pMHC tetramer technology has revolutionized the study of
antigen speciﬁc T-cells. However, one major limitation of this
technique is that pMHCI, and most likely pMHCII, tetramer
staining is dependent on a distinct TCR afﬁnity threshold
(Laugel et al., 2007). Consequently, pMHC tetramers fail to
identify T-cells that express TCRs with low afﬁnity for cognate
antigen; such low afﬁnity interactions characterize TCR/pMHCI
binding in tumor-speciﬁc and autoreactive CD8+ T-cells (Cole
et al., 2007). Here, we demonstrate that a short incubationwith
a reversible PKI such as dasatinib results in threemajor beneﬁts
in terms of pMHC tetramer staining. First, substantial improve-
ments in pMHC tetramer staining intensity are observed. This
effect applies to both CD4+ and CD8+ T-cells (Fig. 1). Indeed, the
beneﬁcial effects are so striking even at low pMHC tetramer
concentrations that dasatinib treatment could be used to
Fig. 10. Dasatinib prevents down-regulation of ‘empty’ TCRs. Proposed model
for the mechanism by which dasatinib enhances cognate tetramer staining.
Dasatinib treatment prevents TCR and coreceptor down-regulation and
maintains these receptors at the cell surface, thereby increasing molecular
availability for further capture of pMHC tetramer from solution.
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mer-induced cell death that has been previously reported to be
an issuewithpMHCI tetramer stainingprotocols (Purbhooet al.,
2001; Xu et al., 2001; Guillaume et al., 2003; Cebecauer et al.,
2005). Third, the beneﬁts of dasatinib treatment are greater for
TCR/pMHCI interactions of weak afﬁnity and, as a result,
dasatinib enhances the detection of low avidity CD8+ T-cells;
this effect increases the number of CD8+ T-cells that can be
detected directly ex vivo, particularly in the setting of tumor-
speciﬁc and autoreactive CD8+ T-cell populations. Such effects
are also likely to apply to CD4+ T-cells, which typically bind
cognate pMHCII antigens with afﬁnities lower than those
reported for pMHCI systems (Cole et al., 2007).
Importantly, no increase in background staining was seen in
any of the systems tested here (Figs. 1B, 1H, 5B & 5C). In fact the
tetramernegativebackgroundwasactually seen todecreasewith
dasatinib treatment in some stainingexperiments (Figs. 4C&5C).
Positive staining of PBMC in the presence of dasatinib only ever
coincided with a positive ELISpot result to the relevant peptide.
Dasatinib proved to be a particularly powerful tool in the
detection of autoreactive CTL from type I diabetic patients. No
increase in the PPI tetramer positive populationwas observed in
healthy donors and indeed staining was only ever seen if a
functional response to the preproinsulin peptide was evident.
Our results suggest that the beneﬁts of dasatinib treatment apply
only to CTL that express TCR speciﬁc for the pMHCI tetramer in
use and capable of recognizing cognate pMHCI (although
function may be impaired in some low avidity CTL populations).
This conclusion is further strengthened by the ﬁnding that the
beneﬁcial effects are TCR mediated and do not involve the CD8coreceptor. Thereforedasatinib facilitates the speciﬁcTCR/pMHCI
interaction rather than the non-speciﬁc pMHCI/CD8 interaction.
Dasatinib prevents TCR downregulation and tetramer
internalization from the cell surface. How does this effect result
in faster tetramer on-rates and the beneﬁcial effects described
above? When an individual pMHC molecule in a pMHC
tetramer engages a cell surface TCR, this engagement can be
either ‘productive’ or ‘non-productive’ in terms of capturing the
tetramer from solution (Fig. 10). A productive engagement
requires a second pMHC in the tetramer to bind a second TCR
before the ﬁrst pMHC dissociates. As a result, the main factor
that determines whether a pMHCI tetramer exhibits stable
binding is likely to be the duration of the primary monomeric
TCR/pMHCI interaction. ‘Non-productive’ engagements are
more likely to occur for low afﬁnity ligands as they dissociate
rapidly from cell surface TCR. Dasatinib would act to prevent
TCR downregulation after ‘non-productive’ engagement
thereby maintaining TCRs at the cell surface where they are
available for future interactions with pMHCI. In addition,
dasatinib treatment is likely to block the internalization of
non-triggered TCRs that has been shown to occur at the same
time as the internalization of pMHCI-engaged TCRs (Nieder-
gang et al., 1997; San Jose et al., 2000). Dasatinib and other
effective PKIs prevent TCR downregulation, acting to maintain
surface TCRs and enabling a higher number of potential
productive engagements with pMHC tetramer as indicated by
the red arrows (Fig. 10). Increased TCR availability at the T cell
surface would increase the likelihood of a ‘productive engage-
ment’ for low afﬁnity ligands. This effect would be less obvious
for higher afﬁnity ligands, where slow TCR/pMHCI off-rates
already increase the likelihood that a second pMHCI arm can
bind before dissociation of the ﬁrst monomeric TCR/pMHCI
interaction. The beneﬁcial effects observed do not involve
signiﬁcant contribution from the CD8 coreceptor suggesting
that CD8 availability at the T cell surface must be sufﬁcient for
pMHCI tetramer staining in the absence of dasatinib treatment.
In summary, we have demonstrated that a short incubation
with reversible PKIs such as dasatinib substantially improves
the staining intensity of cognate T-cells with pMHC tetramers
and can expose concealed antigen-speciﬁc T-cells that bear low
afﬁnity TCRs. These beneﬁts are restricted to cognate T-cells and
are not accompanied by concomitant increases in background
staining. As such, dasatinib has many potential uses;
(i) enhancement of routine pMHCI tetramer staining in the
lab, (ii) conservation of this valuable reagent as the amount
required is signiﬁcantly reduced in the presence of dasatinib,
(iii) detection of low avidity CTL populations which will be of
particular importance for researchers and clinicians studying
diseases characterized by CTL of this type such as chronic viral
infection, auto-immune and neoplastic disease. The beneﬁcial
effects of this reagent also extend to MHCII tetramers, with
which staining is often very poor or not visible at all. We
conclude, that this simple and universally applicable technique
is likely to be beneﬁcial in all studies of antigen-speciﬁc T-cells.
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